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Background: Human bocavirus (HBoV), a parvovirus, is suspected to be an etiologic agent of respiratory disease
and gastrointestinal disease in humans. All mRNAs of HBoV1 are transcribed from a single promoter.
Methods: In this study, we constructed EGFP and luciferase reporter gene vectors under the control of the HBoV1
full promoter (nt 1–252) and its mutated variants, respectively. Fluorescence microscopy was used to observe
expression activities of the EGFP. Dual-luciferase reporter vectors were employed in order to evaluate critical
promoter elements and the effect of NS1 protein on promoter activity.
Results: The HBoV1 promoter activity was about 2.2-fold and 1.9-fold higher than that of the CMV promoter in
293 T and HeLa cells, respectively. The putative transcription factor binding region of the promoter was identified
to be located between nt 96 and nt 145. Mutations introduced in the CAAT box of the HBoV1 promoter reduced
promoter activity by 34%, whereas nucleotide substitutions in the TATA box had no effect on promoter activity. The
HBoV1 promoter activities in 293 T and HeLa cells, in the presence of NS1 protein, were 2- to 2.5-fold higher than
those in the absence of NS1 protein.
Conclusion: The HBoV1 promoter was highly active in 293 T and HeLa cell lines, and the sequence from nt 96 to
nt 145 was critical for the activity of HBoV1 promoter. The CAAT box, in contrast to the TATA-box, was important
for optimum promoter activity. In addition, the transcriptional activity of this promoter could be trans-activated by
the viral nonstructural protein NS1 in these cells.
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Human bocavirus 1 (HBoV1) was first discovered in re-
spiratory samples from children [1] and classified in the
genus Bocavirus (subfamily, Parvovirinae; family, Parvoviri-
dae) [2] with other members, including bovine parvovirus
(BPV), minute virus of canines (MVC), gorilla bocavirus
(GBoV) and porcine bocavirus (PBoV) [3-6]. Three differ-
ent genotype members of Human bocavirus, HBoV2, 3 and
4, have been discovered subsequently in fecal specimens.
The HBoV1 virus is the most frequently identified patho-
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reproduction in any medium, provided the orin respiratory specimens from children under 2 years old
with acute respiratory illnesses, often showing a high pres-
ence of co-infection with other respiratory viruses [7-19].
One of the most frequently observed clinical symptoms in
HBoV1-infected patients is acute wheezing [20,21]. How-
ever, Vicenti et al. [22] reported the detection of HBoV1 in
stool samples from children under 3 years old with acute
gastroenteritis without respiratory tract disease and Mitui
et al. [23] detected HBoV1 in the cerebrospinal fluid of chil-
dren with encephalitis. Therefore, the role of HBoV1 in dis-
ease requires further investigation.
HBoV1 is a linear, single-stranded DNA virus with a gen-
ome of about 5400 nt. Recently, Huang et al. [24] obtained
the sequence of a full-length HBoV1 genome (including
both termini) and demonstrated that this HBoV1 plasmid
replicated and produced viruses in human embryonichis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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detected in HBoV1-positive clinical samples, Lüsebrink
et al. [25] proposed that HBoV1 may have a different rep-
lication mechanism than parvoviruses in general. In the
HBoV1 genome, there are two major open reading frames
(ORFs) encoding non-structural protein NS1, and capsid
proteins VP1 and overlapping VP2, respectively. An add-
itional mid-ORF is thought to encode the non-structural
protein NP1 with an unknown function. All mRNAs of
HBoV1 are transcribed from a single promoter located
near the 5'-terminus of the viral genome [26], similar to
that of the closely related BPV and MVC. Recently, a com-
prehensive transcription profile of HBoV1 by transfecting
a replicative chimeric HBoV1 genome in 293 cells and a
non-replicative genome in human lung epithelial A549
cells was generated and the expression profiles of both the
structural and non-structural proteins of HBoV1 were
studied in detail [27].
The non-structural NS1 protein of parvovirus is
central to the viral life cycle and plays multiple roles,
mediating viral genome transcription, replication, and
packaging. The NS1 protein of parvovirus B19 is es-
sential for the activation of the B19 p6 promoter [28]
and has a positive feedback effect on the activity of
the p6 promoter [29]. Raab et al. [30] demonstrated
that B19-NS1 protein interacted with the p6 promoter
by direct DNA binding to cellular transcription fac-
tors Sp1/Sp3. The P38 promoter of the autonomous
parvovirus minute virus of mice (MVMp) is strongly
trans-activated by the nonstructural protein NS1,
which interacts with the cellular transcription factors
SP1, TFIIA(α/β) and TBP in vitro [31-35]. The tran-
scripts encoding the NS1 of HBoV1 which are either
spliced or unspliced resulted in respectively a large
nonstructural protein NS1 of approximately 100 kDa
comparable to the NS1 of MVC and BPV1, and a
relatively small nonstructural protein NS1-70 of ap-
proximately 70 kDa [27]. However, the functions of
HBoV1-NS1 protein have not been characterized yet.Figure 1 Map of the HBoV1 promoter with potential binding sites for
TATA-box, CAAT-box and Ins. The transcription start site was indicated w
c-Ets, cellular E twenty six domain transcription factor; CREB, cAMP respon
myeloid leukemia gene binding region.Results
Identification of key elements of HBoV1 promoter
The whole promoter region (nt 1–252) was amplified from
the pWHL-1 vector by PCR and verified by sequencing.
The promoter sequence was then analyzed for the presence
of DNA elements known to interact with cellular transcrip-
tion factors using a transcription factor binding site profile
database TFSEARCH (on-line at http://www.cbrc.jp/re-
search/db/TFSEARCH.html) (Figure 1). The analysis of
promoter regions showed that a core region of the pro-
moter, from nt 146 to nt 196, is present, i.e. 91 nucleotides
away from the initiation codon of NS1. The transcription
start site for NS1 was identified at nt 186 by 5' RACE (data
not shown), 66 bp upstream from the ATG translation start
site of NS1 protein, which is similar to Dijkman’s data [26].
The TATA-like sequence was located 32 bp upstream of
the transcription initiator sequence (Ins), and the CAAT
box was identified at nt 131, and most potential cellular
transcription factor binding sites were located from nt 110
to nt 152.
Ubiquitous activity of the HBoV1 promoter in mammalian
cells
The pGL3-Bov-EGFP vector containing nt 1–252 was
transfected into 293 T, A549, HeLa and WI-38 cell lines to
assay the activity of the promoter of HBoV1 in these mam-
malian cells. In parallel, plasmid pEGFP-N1 containing the
EGFP gene under the control of the CMV promoter was
used as a control. The EGFP expression was then observed
by fluorescence microscopy at 48 h post-transfection.
Green fluorescence was detected in all cells transfected with
the vector containing the EGFP gene under the control of
the HBoV1 promoter (Figure 2). Compared to control
transfections with pGL3-pCMV, fluorescence was slightly
stronger in cells transfected with pGL3-Bov-EGFP. Because
of variable efficiency of transfection in diverse cell types
using Lipofectamine reagent, numbers of the four cell lines
positive for EGFP were different. No nonspecific green
fluorescence was found in the control cells.transcription factors indicated (boxes) and essential elements:
ith bold letter in the Ins box. CdxA, caudal-type homeobox protein;
se element binding; NF-Y, CCAAT box-binding factor; AML-la, acute
Figure 2 Detection the EGFP expression under control of the HBoV1 promoter (left panel) and of the CMV promoter (middle panel) in
different cell lines by fluorescence microscopy. Cells transfected with pGL3-EGFP vectors were used as negative controls. Original
magnification 20 ×.
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porter to correct for possible variable transfection effi-
ciencies of the four cell lines. These cell lines were co-
transfected with the pRL-TK and pGL3-(1–252) in order
to determine relative activities of the HBoV1 promoter
in 293 T, WI-38, A549, and HeLa cells. For comparison,
the pGL3-pCMV construct and the pGL3-Basic plasmid,
without any promoter, were used as positive control and
negative control, respectively. The results showed that
the HBoV1 promoter exhibited much higher activity in
these four cell lines compared to the promoter-less con-
trol vector pGL3-Basic (Figure 3). HBoV1 and the CMV
promoters revealed almost the same activity in WI-38
and A549 cells; however, promoter activity of HBoV1
was about 2.2-fold and 1.9-fold higher than that of CMV
in 293 T and HeLa cells, respectively. These data indi-
cated that the HBoV1 promoter was highly active in hu-
man cells.
Analysis of elements of the HBoV1 promoter
Several constructs were created by truncating the 5'- or
3'-terminus sequences of the the promoter P1 (nt 1–
252) and then fused in frame with a luciferase gene to
determine the minimal region required for high tran-
scriptional activity of HBoV1 promoter (Figure 4). After
transfection of HeLa cells with these constructs, lucifer-
ase activity was measured as described in the Methodssection. Results indicated that the full promoter P1 and
some 5'-terminus truncated promoters, including con-
structs P2, P3 and P4, showed almost the same activity,
suggesting that the sequences from nt 1–95 were not
critical for the promoter activity (Figure 5). When the
sequences of the 5'-terminus were further deleted to
reach the position at nt 128 (P5) and nt 145 (P6), pro-
moter activity decreased by 34% and 62%, respectively,
compared to the full promoter P1. These results sug-
gested that the putative transcription factor binding re-
gion, located from nt 96 to nt 145, may be important for
transcriptional activity. The core promoter region from
nt 146 to nt 196 was suggested by promoter prediction
software analysis [26]. However, the construct P8, al-
though containing the purported promoter Ins and
TATA box key elements, showed activity nearly at back-
ground level. When 17 bp sequences upstream of the
core promoter remained to yield the construct P7, which
contained the CAAT box, the promoter activity was in-
creased almost 105-fold compared to the P8 construct.
These data suggested that the additional upstream se-
quences of the core promoter appeared to be required
for the HBoV1 promoter activity.
Two mutant promoter constructs, pGL3-TATAmut
and pGL3-CAATmut, were created as described in the
Methods section to measure the contribution of the
TATA box and CAAT box to promoter activity. As
Figure 3 Comparison of the relative activity of the HBoV1 promoter in different cell lines. Cells were transfected with pGL3-(1–252)/P1
and pGL3-pCMV, respectively. The pGL3-Basic was used as a negative control without any promoter sequence. The mean values and standard
deviation (SD) of three independent experiments are shown (**: p < 0.01).
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CAAT box of pGL3-(1–252) reduced the promoter ac-
tivity by 34%, whereas substitutions in the TATA box
had no effect on promoter activity. We next tested the
effect of two transcription factor binding sites, CREB
and CdxA, which were located in the sequence of nt
96–145, on the activity of HBoV1 promoter. As shown
in Figure 6, the mutant constructs, pGL3-CREBmut and
pGL3-CdxAmut, showed no loss in promoter activity.
NS1 protein trans-activates HBoV1 promoter
The NS1 protein of the parvoviruses exhibits multiple func-
tions, such as transcription factor activities. To examineFigure 4 The HBoV1 full-length and truncated promoters were constr
essential elements and potential binding sites for transcription factors are i
promoter (top line) represent the location and lengths of the promoters.whether the nonstructural protein NS1 of HBoV1 is able to
modulate HBoV1 promoter activity, the P1 construct was
co-transfected with pGL3-pCMV-NS1 construct into
293 T and HeLa cells, and the expression of NS1 protein
was confirmed by Western blotting using an NS1-specific
antibody (Figure 7B). At 48 h post-transfection, transcrip-
tional activities were determined in three independent tests
using luciferase assays. Here, the activity of the HBoV1 pro-
moter in cells co-transfected with P1 and pGL3-pCMV-
NS1mut vector (no NS1 protein expression) was used as a
control. As shown in Figure 7A, the HBoV1 promoter ac-
tivities in the two cell lines in the presence of NS1 protein
were 2- to 2.5-fold higher than those in the absence of NS1ucted and used for analysis of the promoter activity. Promoter
ndicated (shaded boxes). The bold solid lines below the HBoV1
Figure 5 Comparative analysis of luciferase activity following
recombinant plasmids (P1-P8) transfection in HeLa cells. The
cells were harvested at 48 h post-transfection and the luciferase
assay was performed as described in the Methods section. The error
bars indicate standard deviations of three independent experiments
and each performed in triplicate. Co is control value
from pGL3-Basic.
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trans-activated the viral promoter.
Discussion
HBoV1 is a newly identified pathogen associated with
human respiratory tract illnesses. In the present study,
33 of 941 nasopharyngeal aspirates collected from hospi-
talized children with lower respiratory tract infectionsFigure 6 Analysis of transcriptional activity of HBoV1 promoter in He
CREBmut), CdxA binding site at nt 146 (pGL3-CdxAmut), CAAT box at nt 13
obtained by PCR-based site-directed mutagenesis. The pGL3-Basic without
standard deviations of three independent experiments and each performed
initiator sequence.(3.51%) were positive for HBoV1 (data not shown). Next,
we constructed a nearly full-length genome clone with-
out ITR structures at the termini, which resembled
genotype HBoV1, as established by DNA sequence align-
ment. The region of the full promoter from nt 1 to 252,
the sole promoter in the viral genome [26,27], including
the translation initiation codon of the NS1 gene, was
amplified by PCR using plasmid pWHL-1 as a template
and cloned into the pBluescript II vector. Bioinformatic
analysis indicated that the essential elements of the pro-
moter, including TATA-box, CAAT-box, and Ins were
present in this region. The full promoter construct was
transfected into four human cell lines to examine
whether the unique viral promoter is active in mamma-
lian cell lines. The results showed that the promoter was
highly active not only in all tested human cell lines, but
also in other mammalian cells such as porcine and
rabbit cells. Furthermore, in 293 T and HeLa cells, the
activity of the HBoV1 promoter even exceeded that of
the CMV promoter which is well known to be a highly
active in eukaryotic cells. However, the HBoV1 promoter
was not functional in the insect Sf9 cell line (data not
shown). In our recent study, NS1 transcripts from the
left-hand of the viral genome were detected in pWHL-1
transfected 293 T cells and other mammalian cells in-
cluding HeLa, A549, WI-38 cell lines (data not shown),
suggesting that this promoter is unique and active in
most mammalian cells. The HBoV1 promoter may be-
come an attractive choice when a strong promoter is
needed in a variety of vertebrate cells. No viral DNA
replication was detected by the Southern-blot methodLa cells. Mutants for putative CREB binding site at nt 118 (pGL3-
1 (pGL3-CAATmut) and TATA box at nt 155 (pGL3-TATAmut) were
any promoter was used as a negative control. The error bars indicate
in triplicate. Black rhombic symbols, mutant sites; Ins, transcription
Figure 7 Trans-activation of the HBoV1 promoter by the NS1
protein. (A) The luciferase activity of the construct pGL3-(1–252) in
293 T and HeLa cells in the presence of the NS1 expression. Cells
co-transfected with pGL3-(1–252) and mNS1 constructs in the
absence of the NS1 were used as controls. The relative luciferase
activity was calculated as the ratio between the pGL3-(1–252)
activity and the control plasmid pRL-TK activity. The error bars
indicate standard deviations of three independent experiments and
each was performed in triplicate. (B) Detection of the NS1 protein in
cells co-transfected with pGL3-(1–252) and WT-NS1 constructs by
Western blot assay. Actin was used as a loading control. WT-NS1,
pGL3-pCMV-NS1; mNS1, pGL3-pCMV-NS1mut. The mean values and
standard deviation (SD) of three independent experiments are
shown (**: p < 0.01).
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plasmid implicating that ITRs were essential for viral
DNA replication during infection.
Promoters with different lengths were constructed by
truncating its sequence at the 5'- or 3'-terminus, or at both
ends, to determine the minimal sequence required for max-
imal activity. Luciferase assays showed that the region of nt
1–95 at the 5'-terminus did not contribute to the full pro-
moter activity. The core promoter (P8) including Ins and
TATA box exhibited low activity and a mutant of the TATA
motif had no effect on the promoter activity. These results
indicated that the TATA box in the HBoV1 promoter is not
required for promoter activity. However, upon addition of
upstream sequence to include the regulatory element
CAAT box (P7), promoter activity increased. Mutations in
the CAAT box had also an effect on the promoter activity.
The promoter activity diminished dramatically when the se-
quences from nt 96 to nt 145 were deleted, demonstrating
that it contained key transcription regulatory elements.
However, potential CREB and CdxA binding sites wereshown, by mutant assays, not to contribute to promoter
activity.
NS1, a major parvovirus non-structural protein is a
nuclear phosphoprotein involved in essential stages of
the viral life cycle. The NS1 of human parvovirus B19
has been shown to trans-activate the p6 promoter
[29]. Chen et al. reported that the NS1 protein of
HBoV1 was also localized in the nucleus [27], how-
ever, the role of HBoV1 NS1 protein has not been
characterized. We therefore examined the effect of
the NS1 protein on the HBoV1 promoter and found
that this protein activated in trans the activity of the
promoter in 293 T and HeLa cells. It is possible that
the NS1 protein functions through binding to the
promoter region or, indirectly, by interacting with
host transcription factors. Deletion of the DNA ele-
ments, such as an ATF/CREB consensus site, of the
P6 promoter in B19, led to a great reduction of
trans-activation by NS1 to only 30% of that of the
wild-type promoter [36]. A sequence element similar
to the CREB site is also present within the HBoV1
promoter region: 5'-TGACGTAT-3' (nt 118–125),
which is proximal to the TATA box and may be a pu-
tative site for binding by the NS1 protein (Figure 1).
In summary, this work provides a framework for fur-
ther characterization of the promoter and study of
the mechanism of transcription and expression of the
viral genome. Further investigation is needed to eluci-
date trans-activation mechanisms by viral nonstruc-
tural proteins and cellular transcription factors.
Conclusion
HBoV1 is a parvovirus associated with respiratory dis-
ease in humans. The HBoV1 promoter was active
with different strengths in all tested mammalian cell
lines transfected with constructs of EGFP and lucifer-
ase report gene under the control of the HBoV1 pro-
moter. The activity of this promoter is higher than
that of CMV promoter in 293 T and HeLa cells. The
regulatory element CAAT box sustained an enhanced
activity of the HBoV1 core promoter. Moreover, the
promoter was trans-activated by NS1 protein, suggest-
ing that NS1 protein plays an important role in
HBoV1 transcriptional regulation.
Methods
Construction of the HBoV1 promoter expression plasmids
A large internal fragment containing 5299 nts of the
HBoV1 genome was amplified from DNA extracted
from nasopharyngeal aspirate samples with the spe-
cific primers based on the published HBoV1 sequence
(GenBank accession number ID: DQ000496) and
cloned into SalI–XbaI sites of the pBluescript SKII
vector to generate the pWHL-1 (GenBank accession
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were created by PCR amplification of the respective
segments with plasmid pWHL-1 and pEGFP-N1 as
templates. The HBoV1 promoter (nt 1–252) and the
cytomegalovirus immediate early (CMV-IE) promoter
were cloned into pGL3-Basic (Promega, Beijing, China)
to result in pGL3-(1–252)/P1 and pGL3-pCMV, re-
spectively. The construct pGL3-(1–252)/P1 was used
subsequently as a template for generation of a series of
truncated mutants of the HBoV1 promoter by PCR.
These mutants were designated as pGL3-(32–252)/P2,
pGL3-(64–252)/P3, pGL3-(96–252)/P4, pGL3-(128–252)/
P5, pGL3-(145–252)/P6, pGL3-(128–196)/P7 and pGL3-
(145–196)/P8 respectively (Figure 4). The substitution
mutant pGL3-(CREBmut) was made by PCR-based mu-
tagenesis from pGL3-(1–252), whereby the sequence
TGACG motif at nt 118 was mutated to TCAAT. Simi-
larly, in the mutant pGL3-(CAATmut), the initiator
sequence at nt 131 was mutated from CCAAT to
TTAAT; in the mutant pGL3-(CdxAmut), the initiator
sequence at nt 146 was mutated from TATT to
GAGG; and in the mutant pGL3-(TATAmut), the ini-
tiator sequence at nt 155 was mutated from TATAT
to GAGAG (Figure 6). pGL3-Bov-EGFP and pGL3-
pCMV-NS1 plasmids were constructed by replacing
the luciferase gene with the GFP gene of the pGL3-
(1–252) and the luciferase gene with the HBoV1 NS1
gene (nt 253–2172) of pGL3-pCMV vector, respect-
ively. The NS1 mutant plasmid, designated pGL3-
pCMV-NS1mut, was constructed by mutating the start
codon ATG to TAA. All constructs were verified by
sequencing. pRL-TK served as an internal control in
the luciferase reporter assay.
Cell lines and DNA transfection
Human embryonic kidney cells (293 T), human cervical
carcinoma cells (HeLa), human lung epithelial cells
(A549) and SV40-immortalized human lung fibroblasts
(WI-38) were maintained in Dulbecco's modified Eagle's
medium (DMEM) with 10% fetal bovine serum (FBS)
and antibiotics in 5% CO2 at 37°C. The cells grown in
24-well plates at 5 × 104 cells per well were transfected
with 1 μg of plasmid; the Lipofectamine and Plus re-
agents (Invitrogen, Grand Island, NY, USA) were used
following the manufacturers' instructions. For co-
transfection, 293 T and HeLa cells were transfected with
recombinant plasmids in 96-well plates at 1 × 104 cells
per well, respectively.
Detection of HBoV1 promoter activity
Observation of EGFP
For detection of HBoV1 promoter activity, mammalian cell
lines including 293 T, A549, HeLa and WI-38 were trans-
fected with the pGL3-Bov-EGFP construct and the pEGFP-N1 control vector in 24-well plates. The vector pGL3-
EGFP, which contains the EGFP gene without any pro-
moter, was used as a negative control. After 48 h, cells were
observed by fluorescence microscopy and pictures were ac-
quired by NIS-Elements F 2.20 software.
Luciferase assay
To compare the activity between HBoV1 promoter and
CMV promoter, 293 T, A549, HeLa and WI-38 cells, culti-
vated in 96-well plates, were transfected with 50 ng of
pGL3-(1–252) and pGL3-pCMV, respectively. For HBoV1
promoter strength analysis, HeLa cells cultivated in 96-well
plates were respectively transfected with 50 ng of the pro-
moter mutated constructs. To determine whether the
HBoV1 promoter can be regulated by the NS1 protein,
293 T and HeLa cells were co-transfected with 50 ng of
pGL3-(1–252) and 200 ng of pGL3-pCMV-NS1, respect-
ively. Cells co-transfected with pGL3-(1–252) and pGL3-
pCMV-NS1mut were used as a control. As an internal con-
trol, production of a second type of luciferase derived from
Renilla reniformis was achieved by co-transfecting the cells
with plasmid pRL-TK (5 ng) together with the promoter-
luciferase constructs. At 48 h post-transfection, the cells
were harvested and lysed with lysis buffer (Promega). The
assays for the Photinus and Renilla luciferase activities were
performed sequentially according to the Dual-luciferase
assay kit manual (Promega). All tests were performed in
triplicate.
Western blotting for detection of NS1 expression
To detect the NS1 expression in cells co-transfected
with pGL3-(1–252) and pGL3-pCMV-NS1 by Western
blots, 293 T and HeLa cells were transfected with
the two constructs as stated above. At 48 h post-
transfection, cells were lysed with RIPA buffer con-
taining protease inhibitors (PMSF). Total cellular proteins
were separated by 10% SDS-PAGE and transferred onto
nitrocellulose membranes. The membrane was blocked
with TBS containing 5% skimmed milk for 1 h at room
temperature and then incubated for 1 h with the poly-
clonal anti-NS1 mouse antibody as primary antibody at
a 1:2000 dilution. Finally, the membrane was washed
with blocking buffer and then incubated with peroxidase-
conjugated goat anti-mouse immunoglobulin G (Promoter
biotechnology, China) as a secondary antibody for 1 h
at room temperature. The bands were visualized by
3-amino-9-ethylcarbazole (AEC). Cells co-transfected
with pGL3-(1–252) and pGL3-pCMV-NS1mut were
used as a control. The mouse anti-NS1 polyclonal
antiserum was prepared by our laboratory. The mice
were obtained from the facility in Wuhan Institute of
Virology and the study was approved by the institutional
Animal Experiment Commission in accordance with the
Chinese regulations on animal experimentation.
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Statistical analyses were performed with SPSS, version 13.0.
We expressed continuous variables as the median +/−
standard deviation. A p value less than 0.05 was con-
sidered statistically significant.
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